PCM Encore’s Halozyme HALO Stock Holding History

PCM Encore’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$256K	Sell	3,269 -19	-0.6%	-$1.3K	0.05%	369
2026 Q1	$213K	Sell	3,288 -24	-0.7%	-$1.69K	0.04%	403
2025 Q4	$223K	Buy	+3,312	New	+$223K	0.05%	378

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

PCM Encore's HALO Position: Q2 2026 in Review

PCM Encore reduced its Halozyme (HALO) stake by 0.58% in Q2 2026, selling an estimated $1.3K and leaving 3,269 shares worth $256K. The position accounts for 0.05% of the portfolio, ranked #369.

PCM Encore first reported a position in HALO in Q4 2025 and has held it in 3 quarters since. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

PCM Encore held 3,269 shares of Halozyme worth $256K as of Q2 2026.
PCM Encore sold 19 Halozyme shares in Q2 2026, an estimated $1.3K.
Halozyme made up 0.05% of PCM Encore's portfolio in Q2 2026, its #369 holding.
PCM Encore first reported a position in Halozyme in Q4 2025 and has held it in 3 quarters since.
668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on PCM Encore's 13F filing for Q2 2026, filed 11 Aug 2026.